FIELD: medicine.
SUBSTANCE: invention relates to medicine, in particular to experimental pharmacology. Method is proposed for inhibiting the nuclear factor kappa B in a cell culture comprising adding a bacterial lipopolysaccharide at a concentration of 1 mcg/ml to a freshly isolated standard ficoll density gradient test for mononuclear blood cells of Wistar rats, characterized in that 2-ethyl-6-methyl-3-hydroxypyridinium L-2,6-diaminohexanoate is then added to this mixture at a final concentration of 35 mcg/ml.
EFFECT: technical result consists in the expressed inhibition of the nuclear factor kappa B in the cell culture and in the favorable safety profile.
1 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR INHIBITING NUCLEAR FACTOR KAPPA B WITH USE OF 5-HYDROXYNICOTINATE 3-(2,2,2-TRIMETHYLHYDRAZINIUM) POTASSIUM PROPIONATE IN CELL CULTURE | 2017 |
|
RU2674443C1 |
| METHOD OF INHIBITING KAPPA NUCLEAR FACTOR WITH THE USE OF POTASSIUM 5-HYDROXYNICOTINATE IN A CELL CULTURE | 2017 |
|
RU2675693C1 |
| ANTIOXIDANT, PHOTOPROTECTIVE AND GEROPROTECTIVE AGENT | 2011 |
|
RU2458714C1 |
| METHOD OF CORRECTING BACTERIAL PURULENT MENINGITIS BY 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINIUM 2,6-DICHLOROPHENYL(AMINO)PHENYL ETHANOATE UNDER EXPERIMENTAL CONDITIONS | 2019 |
|
RU2724883C1 |
| EMPLOYMENT OF (R)-ARYLPROPIONIC ACIDS TO PREPARE DRUGS FOR TREATMENT OF HUMANS AND ANIMALS LIABLE TO BE THERAPEUTICALLY AFFECTED VIA NF-κB ACTIVATION INHIBITION | 2000 |
|
RU2250103C2 |
| USE OF ARSENIC COMPOUNDS TO TREAT TISSUE OR ORGAN REJECTION | 2013 |
|
RU2665362C2 |
| METHOD FOR CORRECTING THE NEUROLOGICAL STATUS WITH 2-ETHYL-6-METHYL-3-HYDROXY PYRIDINIUM-N-ACETYLAMINOACETATE IN CASE OF BRAIN DAMAGE DUE TO INTRACEREBRAL HEMORRHAGE IN THE EXPERIMENT | 2022 |
|
RU2786315C1 |
| USE OF ARSENIC COMPOUNDS FOR PAIN MANAGEMENT AND INFLAMMATION TREATMENT | 2008 |
|
RU2630574C2 |
| PHARMACEUTICAL FORMULATION FOR TREATING DISEASES ASSOCIATED WITH ENDOTHELIAL DYSFUNCTION | 2012 |
|
RU2504375C1 |
| METHOD FOR EARLY PREDICTION OF MISCARRIAGE ASSOCIATED WITH REACTIVATION OF CYTOMEGALOVIRUS INFECTION | 2022 |
|
RU2787451C1 |
